PIPELINE

Pioneering Drugs for Emerging Targets

Discovery & Development

Our pipeline targets lineage-based vulnerabilities across multiple tumor types, informed by integrative biology and translational science.

    • Program 1: Non-covalent inverse agonist for the treatment of urothelial cancers
    • Program 2: Lineage-directed activator for Acute Myeloid Leukemia (AML)
    • Program 3: Adaptive combination strategy to overcome resistance pathways

    Each program reflects our philosophy — deep science, precise targeting, real patient impact.

    Program

    Discovery

    IND-enabling

    Phase l

    Program I

    Oncology (UCa, GI): >$4B/year market
    Obesity/NASH (TBD): >$10B/year market

    • First-in-Class 50% 50%
    Program 2

    Oncology (AML MPN): >$2B/year market
    Neuro/CVM: >$3B/year market

    • First-in-Class 30% 30%
    Program 3

    Oncology (prostate): >$8B/year market

    • Potential Best-in-Class 25% 25%
    Lineage Transcription Factors

    Oncology: prostate:>$10B/year market
    Breast :>$8B/year market

    • First-in-Class Targets 15% 15%
    Manufacturing

    Why Core Biology Matters

    Cancer is more than a set of mutations. The lineage programs that define a tumor’s identity control how it grows, survives, and escapes treatment. By drugging these core dependencies, we aim to:

    • Expand precision medicine to patients beyond genomics
    • Address the root biology of resistant and aggressive cancers
    • Unlock new therapeutic targets for the treatment of patients with unmet needs
    • Treat a larger patient population than traditional precision medicine approaches

    This approach has the potential to reshape how cancers are treated at the molecular and cellular core.